TREATMENT OF PROSTATE CANCER USING CHIMERIC ANTIGEN RECEPTORS

摘要

Provided herein are methods of treating neuroendocrine prostate cancer (NEPC) with immune cells comprising a CEACAM5 chimeric antigen receptor (CAR). Also provided are methods of reducing or eliminating NEPC cancer cells with immune cells comprising a CEACAM5 CAR. Also provided are methods of treating a cancer with a molecular signature that is similar to a molecular signature of NEPC (e.g., small cell lung cancer (SCLC), small cell carcinoma of the pancreas (SCCP), or small cell prostate cancer).